These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18441381)

  • 1. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
    Wilkin TJ; Taylor B; Olender S; Hammer SM
    Top HIV Med; 2008; 16(1):31-60. PubMed ID: 18441381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The newest developments in anti-HIV-1 drugs].
    Zhang XQ
    Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New antiretroviral drug classes in HIV therapy].
    Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
    MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiretroviral treatment update from the 17th International AIDS Conference.
    Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
    AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Researchers explore new anti-HIV agents.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1635-7. PubMed ID: 11926873
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in antiretroviral therapy.
    Jones J; Taylor B; Wilkin TJ; Hammer SM
    Top HIV Med; 2007; 15(2):48-82. PubMed ID: 17485787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 14. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in antiretroviral therapy.
    Sobieszczyk ME; Talley AK; Wilkin T; Hammer SM
    Top HIV Med; 2005; 13(1):24-44. PubMed ID: 15849370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartlett JG
    Hopkins HIV Rep; 1998 Mar; 10(2):1-10, 12. PubMed ID: 11365136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical pharmacology of antiretrovirals in development.
    Winston A; Mallon PW; Boffito M
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
    Di Biagio A; Bruzzone B; Rosso R; Viganò O; Icardi G; Viscoli C; Rusconi S
    AIDS Patient Care STDS; 2008 May; 22(5):355-7. PubMed ID: 18373415
    [No Abstract]   [Full Text] [Related]  

  • 20. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.